Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat

Journal of Pharmacy and Bioallied Sciences

Volumn 4, Issue 1, 2012, Pages 76-83

  Teixeira, M ^a,b   Rodrigues Santos, P ^b   Garrido, P ^a   Costa, E ^c,d   Parada, B ^a   Sereno, J ^a   Alves, R ^e   Belo, L ^d,f   Teixeira, F ^a   Santos Silva, A ^d,f   Reis, F ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

Author keywords

Apoptosis; cardiovascular protection; gene expression; moderate chronic renal failure; proliferation angiogenesis

Indexed keywords

CASPASE 3; CASPASE 9; CYTOCHROME C; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIAPOPTOTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BAX GENE; BCL2 GENE; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EPO GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE PRODUCT; HEART PROTECTION; IL 2 GENE; IMMUNOLOGY; INFLAMMATION; MALE; NF KB GENE; NONHUMAN; NOS2 GENE; NOS3 GENE; OXIDATIVE STRESS; PARTIAL NEPHRECTOMY; PCNA GENE; PRIORITY JOURNAL; RAT; TNF A GENE; TREATMENT DURATION; VEGF GENE;

RATTUS;

EID: 84856859990     PISSN: None     EISSN: 09757406     Source Type: Journal    
DOI: 10.4103/0975-7406.92743     Document Type: Article

References (48)

1. Deicher R, Hörl WH. Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2003;12:139-43. (Pubitemid 36288313)
2. Miranda Sde P, Macedo RN, Silva Júnior GB, Daher Ede F. Cardio-renal syndrome: Pathophysiology and treatment. Rev Assoc Med Bras 2009;55:89-94.
3. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular disease. Eur Heart J 2004;25:285-91.
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anaemia on cardiomyopathy morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61. (Pubitemid 26231466)
5. Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-the experience of the Lombardy dialysis Registry. Nephrol Dial Transplant 1998;13:1642-4. (Pubitemid 28306788)
6. Latini R, Brines M, Fiordaliso F. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev 2008;13:415-23.
7. Mastromarino V, Volpe M, Musumeci MB, Autore C, Conti E. Erythropoietin and the heart: Facts and perspectives. Clin Sci (Lond) 2011;120:51-63.
8. van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008;4:47-57. (Pubitemid 350308210)
9. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90. (Pubitemid 28385655)
10. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006;48:2161-7. (Pubitemid 44855436)
11. Garrido P, Reis F, Costa E, Teixeira-Lemos E, Parada B, Alves R, et al. Characterization of a rat model of moderate chronic renal failure-focus on hematological, biochemical, and cardio-renal profiles. Ren Fail 2009;31:833-42.
12. Garrido P, Reis F, Costa E, Almeida A, Parada B, Teixeira-Lemos E, et al. Effect of recombinant human erythropoietin in a rat model of moderate chronic renal failure-focus on inflammation, oxidative stress and function/ renoprotection. The Open Drug Discovery J 2010;2:25-32.
13. Teixeira AM, Garrido P, Santos P, Alves R, Parada B, Costa E, et al. Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure. Ren Fail 2010;32:1073-80.
14. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 2004;286:R977-88. (Pubitemid 38661383)
15. Jelkmann W. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol 2007;435:179-97.
16. Lappin T. The cellular biology of erythropoietin receptors. Oncologist 2003;8 Suppl 1:15-8. (Pubitemid 36331743)
17. Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int 2009;75:682-8.
18. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
19. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-ΔΔCT. Method. Methods 2001;25:402-8. (Pubitemid 34164012)
20. Bogoyevitch MA. An update on the cardiac effects of erythopoietin cardioprotetion by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63:208-16. (Pubitemid 38900835)
21. Manolis AS, Tzeis S, Triantafyllou K, Michaelidis J, Pyrros I, Sakellaris N, et al. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:355-75. (Pubitemid 41631546)
22. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974-8. (Pubitemid 24139555)
23. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an akt-dependent pathway. Biochem Biophys Res Commun 2003;308:990-4. (Pubitemid 36976556)
24. Raddino R, Robba D, Caretta G, Bonadei I, Teli M, Zanini G, et al. Erythropoietin: a new perspective in cardiovascular therapy. Monaldi Arch Chest Dis 2008;70:206-13.
25. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004;22:63-9. (Pubitemid 40228212)
26. Ma R, Xiong N, Huang C, Tang Q, Hu B, Xiang J, et al. Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/Akt signalling pathway. Neuropharmacology 2009;56:1027-34.
27. van der Meer P, van Veldhuisen DJ. New applications of erythropoietin in cardiovascular disease: from haematopoiesis to cardiac protection. Ned Tijdschr Geneeskd 2008;152:923-7. (Pubitemid 351804260)
28. Moriyama MT, Tanaka T, Morita N, Ishii T, Chikazawa I, Suga K, et al. Renal protective effects of erythropoietin on ischemic reperfusion injury. Cell Transplant 2010;19:713-21.
29. Pallet N, Bouvier N, Legendre C, Beaune P, Thervet E, Choukroun G, et al. Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 2010;61:71-5.
30. Toba H, Sawai N, Morishita M, Murata S, Yoshida M, Nakashima K, et al. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 2009;612:106-14.
31. Wang W, Zhang J. Protective effect of erythropoietin against aristolochic acid-induced apoptosis in renal tubular epithelial cells. Eur J Pharmacol 2008;588:135-40.
32. Timmer SA, De Boer K, Knaapen P, Götte MJ, Van Rossum AC. The potential role of erythropoietin in chronic heart failure: From the correction of anemia to improved perfusion and reduced apoptosis? J Card Fail 2009;15:353-61.
33. Fu P, Arcasoy MO. Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. Biochem Biophys Res Commun 2007;354:372-8. (Pubitemid 46161367)
34. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308:990-4. (Pubitemid 36976556)
35. Bernhardt WM, Eckardt KU. Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury. Curr Opin Crit Care 2008;14:621-6.
36. Schindler R, Senf R, Frei U. Influencing the inflammatory response of haemodialysis patients by cytokine elimination using large-pore membranes. Nephrol Dial Transplant 2002;17:17-9. (Pubitemid 34093002)
37. Hung CY, Chen YA, Chou CC, Yang CS. Nutritional and inflammatory markers in the prediction of mortality in Chinese hemodialysis patients. Nephron Clin Pract 2005;100:c20-6.
38. Chatterjee PK. Pleiotropic renal actions of erythropoietin. Lancet 2005;365:1890-2. (Pubitemid 40744968)
39. Chang YK, Choi DE, Na KR, Lee SJ, Suh KS, Kim SY, et al. Erythropoietin attenuates renal injury in an experimental model of rat unilateral ureteral obstruction via anti-inflammatory and anti-apoptotic effects. J Urol 2009;181:1434-43.
40. Qin C, Xiao YB, Zhong QJ, Chen L, Wang XF. Anti-inflammatory effect of erythropoietin pretreatment on cardiomyocytes with hypoxia/reoxygenation injury and the possible mechanism. Chin J Traumatol 2008;11:352-8.
41. Costa E, Lima M, Alves JM, Rocha S, Rocha-Pereira P, Castro E, et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 2008;28:268-75.
42. Debska-Slizien A, Rutkowski B, Manitius J, Zdrojewski Z, Szołkiewicz M, Bułło B, et al. Influence of erythropoietin on immunological system of patients with chronic renal failure. Pol Merkur Lekarski 2003;15:326-7.
43. Efthimiadou A, Pagonopoulou O, Lambropoulou M, Papadopoulos N, Nikolettos NK. Erythropoietin enhances angiogenesis in an experimental cyclosporine A-induced nephrotoxicity model in the rat. Clin Exp Pharmacol Physiol 2007;34:866-9. (Pubitemid 47083967)
44. Shivji KK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992;69:367-74.
45. Essers J, Theil AF, Baldeyron C, van Cappellen WA, Houtsmuller AB, Kanaar R, et al. Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell Biol 2005;25:9350-9. (Pubitemid 41507836)
46. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 2001;16:932-8. (Pubitemid 32440364)
47. Schmeding M, Boas-Knoop S, Lippert S, Ruehl M, Somasundaram R, Dagdelen T, et al. Erythropoietin promotes hepatic regeneration after extended liver resection in rats. J Gastroenterol Hepatol 2008;23:1125-31. (Pubitemid 352019375)
48. Johnson DW, Forman C, Vesey DA. Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology (Carlton) 2006;11:306-12. (Pubitemid 44086875)